Sökning: WFRF:(Nordenskjöld Bo 1940 ) >
Amplification of HS...
-
Gunnarsson, Cecilia,1970-Linköpings universitet,Onkologi,Hälsouniversitetet
(författare)
Amplification of HSD17B1 and ERBB2 in primary breast cancer
- Artikel/kapitelEngelska2003
Förlag, utgivningsår, omfång ...
-
2003-01-14
-
Springer Science and Business Media LLC,2003
-
printrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:liu-24842
-
https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-24842URI
-
https://doi.org/10.1038/sj.onc.1206078DOI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:1950057URI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
Estrogens play a crucial role in the development of breast cancer. Estradiol can be produced in the breast tissue in situ, and one of the enzymes involved in this process is 17β-hydroxysteriod dehydrogenase (17β-HSD) type 1 that catalyzes the interconversion of estrone (E1) to the biologically more potent estradiol (E2). The gene coding for 17β-HSD type 1 (HSD17B1) is located at 17q12-21, close to the more studied ERBB2 and BRCA1. The aim of this study was to investigate if HSD17B1 shows an altered gene copy number in breast cancer. We used real-time PCR and examined 221 postmenopausal breast tumors for amplification of HSD17B1 and ERBB2. In all, 32 tumors (14.5%) showed amplification of HSD17B1 and 21% were amplified for ERBB2. Amplification of the two genes was correlated (P = 0.00078) and in 14 tumors (44%) with amplification of HSD17B1, ERBB2 was co amplified. The patients with amplification in at least one of the genes had a significantly worse outcome than patients without (P = 0.0059). For estrogen receptor (ER)-positive patients who received adjuvant tamoxifen, amplification of HSD17B1 was related to decreased breast cancer survival (P = 0.017), whereas amplification of ERRB2 was not. Amplification of HSD17B1 might be an indicator of adverse prognosis among ER-positive patients, and possibly a mechanism for decreased benefit from tamoxifen treatment.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Ahnström, Marie,1976-Linköpings universitet,Onkologi,Hälsouniversitetet(Swepub:liu)marah62
(författare)
-
Kirschner, KristinaLinköpings universitet,Kirurgi,Hälsouniversitetet
(författare)
-
Olsson, Birgit,1946-Department of Oncology, Huddinge University Hospital, Stockholm, Sweden(Swepub:liu)birol93
(författare)
-
Nordenskjöld, Bo,1940-Linköpings universitet,Onkologi,Hälsouniversitetet(Swepub:liu)bono64
(författare)
-
Rutqvist, Lars ErikDepartment of Oncology, Huddinge University Hospital, Stockholm, Sweden
(författare)
-
Skoog, LambertKarolinska Institutet
(författare)
-
Stål, Olle,1952-Linköpings universitet,Onkologi,Hälsouniversitetet(Swepub:liu)ollst87
(författare)
-
Linköpings universitetOnkologi
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Oncogene: Springer Science and Business Media LLC22:1, s. 34-400950-92321476-5594
Internetlänk
Hitta via bibliotek
-
Oncogene
(Sök värdpublikationen i LIBRIS)
Till lärosätets databas
- Av författaren/redakt...
-
Gunnarsson, Ceci ...
-
Ahnström, Marie, ...
-
Kirschner, Krist ...
-
Olsson, Birgit, ...
-
Nordenskjöld, Bo ...
-
Rutqvist, Lars E ...
-
visa fler...
-
Skoog, Lambert
-
Stål, Olle, 1952 ...
-
visa färre...
- Artiklar i publikationen
-
Oncogene
- Av lärosätet
-
Linköpings universitet
-
Karolinska Institutet